Overview

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Status:
Completed

Trial end date:
2016-04-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether a tablet form of azacitidine that taken by mouth is safe. This Phase I study will also look at different doses and different treatment schedules in order to better understand the effects (positive and negative) of oral azacitidine on the body and on the disease MDS, AML and CMML.

Phase:

Phase 1

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

Azacitidine
Cc-486